What is Qualigen Therapeutics, Inc.'s earnings per share (EPS)?

Qualigen Therapeutics, Inc. (QLGN) reported diluted earnings per share of -$8.11 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Qualigen Therapeutics, Inc. (QLGN) Financials

QLGN

FY2025 annual

Revenue Not reported for FY2025

Net Income -$17.0M -171.1% YoY

EPS (Diluted) -$8.11 YoY not available

Operating Cash Flow -$7.0M -9.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QLGN SEC filings page.

This page shows Qualigen Therapeutics, Inc. (QLGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI QLGN FY2025 2026-10-03

FY2025 shows a financing-led balance-sheet rebuild alongside losses that still outpace the business’s operating cash generation.

From FY2024 to FY2025, the net loss widened from $6.3M to $17.0M, while operating cash flow moved only from -$6.3M to -$7.0M. That gap means accounting losses expanded faster than cash use in operations, making reported earnings a weaker guide to near-term cash demands.

FY2025 assets expanded to $31.3M as financing cash flow reached $41.0M, while operating cash flow remained negative; the balance-sheet expansion came from financing rather than internal cash generation. Liabilities were $3.3M against $31.3M of assets, and the current ratio was 9.3x, indicating substantial reported short-term liquidity at period-end.

Operating loss rose from $5.8M in FY2024 to $13.2M in FY2025 alongside higher SG&A spending. R&D fell from $1.2M to $185K, leaving the latest cost profile more administrative than development-focused while the available data provides no recent revenue base to demonstrate sales conversion.

Financial Health Signals

Financial health score not available

Qualigen Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Qualigen Therapeutics, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Qualigen Therapeutics, Inc. reported a net loss of $17.0M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Qualigen Therapeutics, Inc. reported an operating loss of $13.2M against $989K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$6.1M

YoY-129.7%

Qualigen Therapeutics, Inc. reported -$6.1M in net income in Q1 2026. This represents a decrease of 129.7% from the same quarter a year earlier.

EPS (Diluted)

-$0.79

Qualigen Therapeutics, Inc. earned -$0.79 per diluted share (EPS) in Q1 2026.

Revenue

Not reported for Q1 2026.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$6.2M

YoY+20426.7%

QoQ-67.9%

5Y CAGR-22.3%

10Y CAGR-7.9%

Qualigen Therapeutics, Inc. held $6.2M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

20M

5Y CAGR-6.8%

10Y CAGR+9.0%

Qualigen Therapeutics, Inc. had 20M shares outstanding in Q1 2026.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-27.8%

YoY+7958.5pp

Qualigen Therapeutics, Inc.'s ROE was -27.8% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 7958.5 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$5K

YoY-84.7%

Qualigen Therapeutics, Inc. invested $5K in research and development in Q1 2026. This represents a decrease of 84.7% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

QLGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QLGN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	N/A	N/A	N/A	$5.0M-11.9%	$5.7M+31.3%	$4.3M	$5.6M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$113K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$689K+9.5%	$630K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$185K-84.6%	$1.2M-77.0%	$5.2M+16.1%	$4.5M-61.7%	$11.7M	N/A	$6.1M	$12.3M+326.6%	$2.9M-78.4%	$13.3M+488.1%	$2.3M+1883.9%	$114K
SG&A Expenses	N/A	$8.8M+109.8%	$4.2M-31.0%	$6.1M-40.7%	$10.3M-12.4%	$11.7M	N/A	$4.6M	$5.4M+13.5%	$4.8M-2.1%	$4.9M-23.8%	$6.4M+225.1%	$2.0M
Operating Income	N/A	-$13.2M-129.1%	-$5.8M	N/A	-$14.8M+34.9%	-$22.7M	N/A	-$10.8M	-$17.9M-126.4%	-$7.9M+57.2%	-$18.4M-107.1%	-$8.9M-290.4%	-$2.3M
EBITDA	N/A	N/A	N/A	N/A	-$14.7M+34.6%	-$22.5M	N/A	-$10.8M	-$17.9M-126.5%	-$7.9M+57.2%	-$18.4M-107.1%	-$8.9M-291.0%	-$2.3M
Interest Expense	N/A	$989K+8.8%	$909K-40.4%	$1.5M+4532.7%	-$34K-180.6%	$43K	N/A	$283K	N/A	N/A	N/A	N/A	$10K
Income Tax	N/A	$0-100.0%	$6K+232.2%	-$5K-173.2%	$7K+20.7%	$5K	N/A	$4K	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$17.0M-171.1%	-$6.3M	N/A	-$18.6M-4.2%	-$17.9M+12.4%	-$20.4M	-$10.1M	-$16.9M-114.5%	-$7.9M+57.2%	-$18.4M-109.2%	-$8.8M-255.3%	-$2.5M
EPS (Basic)	N/A	-$8.11+53.8%	-$17.55+86.7%	-$132.25-2626.8%	-$4.85+20.5%	-$6.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$8.11	-$17.55	-$132.25	-$3.62	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M	361,587	101,454	4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
R&D Expenses	$5K-84.7%	N/A	$106K-14.5%	$18K-97.6%	$33K-90.9%	N/A	$123K-91.4%	$754K-35.8%
SG&A Expenses	$3.5M+42.2%	N/A	$1.9M+65.1%	$1.4M+41.4%	$2.5M+135.9%	N/A	$1.1M-14.3%	$986K-59.4%
Operating Income	-$4.3M-59.1%	N/A	-$1.4M-12.7%	-$1.7M+3.3%	-$2.7M-91.6%	N/A	-$1.3M+54.3%	-$1.7M+51.7%
Interest Expense	N/A	N/A	$342K+1122.3%	$106K-59.8%	$74K+8.3%	N/A	$28K-92.4%	$264K-30.2%
Income Tax	$0-100.0%	N/A	N/A	N/A	$35-98.0%	N/A	-$2K	-$1K-130.0%
Net Income	-$6.1M-129.7%	N/A	-$2.0M-13.6%	-$1.7M-6.9%	-$2.6M-30.2%	N/A	-$1.8M+50.9%	-$1.6M+54.5%
EPS (Basic)	-$0.79+56.6%	N/A	-$4.68+0.4%	-$1.00+90.4%	-$1.82+89.7%	N/A	-$4.70+85.3%	-$10.37-1402.9%
EPS (Diluted)	-$0.79	N/A	-$4.68	-$1.00	-$1.82	N/A	-$4.70	-$10.37
Diluted Shares (Avg)	8M	N/A	620,694	2M	1M	N/A	387,878	152,065

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA.

QLGN Balance Sheet

QLGN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Total Assets	$31.3M+567.4%	$4.7M+130.5%	$2.0M-89.3%	$19.1M-16.4%	$22.8M-21.6%	$29.1M	$3.7M	$15.3M-32.9%	$22.8M+215.5%	$7.2M-54.9%	$16.0M+441.3%	$3.0M
Current Assets	$31.0M+560.8%	$4.7M+301.5%	$1.2M-89.2%	$10.8M-48.0%	$20.8M-26.3%	$28.2M	$1.6M	$15.3M-33.0%	$22.8M+216.5%	$7.2M-55.0%	$16.0M+470.8%	$2.8M
Cash & Equivalents	$19.3M+1545.9%	$1.2M+192.3%	$402K-94.3%	$7.0M-23.3%	$9.2M-61.7%	$24.0M	$153K	$7.8M-65.5%	$22.6M+221.2%	$7.0M-55.5%	$15.8M+475.8%	$2.7M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	N/A	$1.6M+50.2%	$1.1M+10.7%	$953K	$660K	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$539K0.0%	$539K-34.5%	$822K+33.6%	$616K	$417K	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$626K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M+65.8%	$2.0M-51.5%	$4.1M-59.9%	$10.3M+64.5%	$6.3M-42.1%	$10.8M	$5.6M	$5.9M+119.1%	$2.7M-12.7%	$3.1M+128.8%	$1.4M-92.2%	$17.5M
Current Liabilities	$3.3M+65.8%	$2.0M-51.5%	$4.1M-51.9%	$8.6M+85.7%	$4.6M-55.6%	$10.4M	$5.3M	$5.9M+119.1%	$2.7M-13.6%	$3.1M+131.3%	$1.4M+8.0%	$1.3M
Non-Current Liabilities	$0	$0	$0-100.0%	$1.7M+4.5%	$1.6M+306.8%	$402K	$308K	$0	$0+100.0%	-$34K	$0-100.0%	$16.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$139K	$2.2M	N/A	N/A	N/A	N/A	N/A
Total Equity	$28.0M+943.3%	$2.7M+227.4%	-$2.1M-129.1%	$7.2M-56.3%	$16.6M-9.5%	$18.3M	-$1.9M	$9.4M-53.4%	$20.1M+386.5%	$4.1M-71.8%	$14.7M+201.3%	-$14.5M
Retained Earnings	-$140.0M-13.8%	-$123.1M-5.4%	-$116.8M-13.0%	-$103.4M-22.0%	-$84.7M-26.8%	-$66.8M	-$47.3M	-$70.2M-31.6%	-$53.3M-17.3%	-$45.5M-67.9%	-$27.1M-51.3%	-$17.9M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$23.9M+739.4%	$31.3M+567.4%	$43.5M+1779.4%	$4.0M+641.5%	$2.8M+183.8%	$4.7M+130.5%	$2.3M-46.4%	$534K-95.9%
Current Assets	$23.5M+725.3%	$31.0M+560.8%	$43.5M+1779.3%	$4.0M+641.1%	$2.8M+183.6%	$4.7M+301.5%	$2.3M-32.9%	$534K-89.0%
Cash & Equivalents	$6.2M+20426.7%	$19.3M+1545.9%	$38.8M+9890.2%	$332K+179.4%	$30K-67.6%	$1.2M+192.3%	$388K-81.3%	$119K-79.9%
Total Liabilities	$2.0M-27.9%	$3.3M+65.8%	$4.9M+10.5%	$5.6M+16.7%	$2.8M-37.8%	$2.0M-51.5%	$4.5M-25.2%	$4.8M-51.1%
Current Liabilities	$2.0M-27.9%	$3.3M+65.8%	$4.9M+10.5%	$5.6M+16.7%	$2.8M-37.8%	$2.0M-51.5%	$4.5M-25.2%	$4.8M-43.3%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Total Equity	$21.9M+65909.5%	$28.0M+943.3%	$38.5M+1900.5%	-$1.7M+61.4%	$33K+100.9%	$2.7M+227.4%	-$2.1M-30.5%	-$4.3M-310.3%
Retained Earnings	-$146.1M-16.2%	-$140.0M-13.8%	-$129.4M-5.9%	-$127.4M-5.8%	-$125.7M-5.8%	-$123.1M-5.4%	-$122.2M-6.9%	-$120.4M-8.8%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

QLGN Cash Flow Statement

QLGN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$9.9M	-$7.0M-9.9%	-$6.3M	N/A	-$13.2M+10.1%	-$14.7M	N/A	-$14.5M	-$13.3M-80.2%	-$7.4M+51.4%	-$15.2M-165.8%	-$5.7M-394.4%	-$1.2M
Depreciation & Amortization	N/A	N/A	N/A	$4K-63.0%	$12K-89.3%	$113K	N/A	$6K	$6K0.0%	$6K+9.8%	$5K+168.6%	$2K-44.3%	$3K
Stock-Based Compensation	N/A	$268-99.8%	$128K-88.3%	$1.1M-76.9%	$4.8M-10.0%	$5.3M	N/A	$438K	$646K-27.9%	$895K-34.1%	$1.4M-53.0%	$2.9M+309.2%	$707K
Capital Expenditures	N/A	N/A	N/A	N/A	$165K+22.5%	$134K	N/A	$2K	$2K-73.8%	$8K-4.8%	$8K-52.6%	$17K+1357.9%	$1K
Free Cash Flow	N/A	N/A	N/A	N/A	-$13.4M+9.8%	-$14.9M	N/A	-$14.5M	-$13.3M-80.1%	-$7.4M+51.3%	-$15.2M-165.2%	-$5.7M-395.3%	-$1.2M
Investing Cash Flow	-$24.1M	-$15.9M-732.6%	-$1.9M-145.2%	$4.2M+2394.2%	-$184K-30.0%	-$141K	N/A	$7.0M	-$7.0M-90691.9%	-$8K+4.8%	-$8K	N/A	N/A
Financing Cash Flow	$40.1M	$41.0M+355.1%	$9.0M+1737.8%	-$550K-118.9%	$2.9M-65.5%	$8.4M	N/A	$1.4M	$5.5M-76.1%	$23.0M+256.8%	$6.4M	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$180	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$4.5M-182.8%	-$2.1M+6.5%	-$2.1M-19.0%	-$1.1M+25.5%	-$1.6M-102.8%	-$2.3M+60.0%	-$1.8M-293.6%	-$1.5M+49.6%
Stock-Based Compensation	N/A	N/A	N/A	N/A	$269-99.5%	N/A	$27K-77.1%	$33K-63.9%
Investing Cash Flow	-$8.5M-2688.3%	-$14.1M-1296.9%	-$291K+76.7%	-$1.2M	-$305K	-$1.0M-527.9%	-$1.3M-129.6%	N/A
Financing Cash Flow	-$132K-117.6%	-$3.3M-180.0%	$40.9M+1131.5%	$2.6M+127.2%	$750K+57.9%	$4.1M+3794.0%	$3.3M	$1.1M

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

QLGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QLGN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY20	FY18	FY17	FY16	FY15	FY14
Gross Margin	N/A	N/A	N/A	N/A	12.2%-2.4pp	14.6%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-296.2%	-400.8%	N/A	-195.1%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-374.0%	-316.6%	-474.2%	-182.3%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-60.7%+172.9pp	-233.6%	N/A	-257.6%-149.6pp	-108.0%+3.6pp	-111.6%	N/A	-179.7%-140.6pp	-39.1%+405.3pp	-444.4%-384.6pp	-59.8%	N/A
Return on Assets	-54.2%+79.3pp	-133.6%	N/A	-97.7%-19.3pp	-78.4%-8.3pp	-70.1%	-272.4%	-110.1%-75.7pp	-34.4%+219.6pp	-254.0%-199.3pp	-54.8%+28.7pp	-83.5%
Current Ratio	9.30+7.0x	2.33+2.1x	0.28-1.0x	1.26-3.2x	4.49+1.8x	2.71	0.30	2.57-5.8x	8.42+6.1x	2.30-9.5x	11.82+9.6x	2.23
Debt-to-Equity	0.12-0.6x	0.75	N/A	1.43+1.0x	0.38+0.4x	0.01	N/A	0.63+0.5x	0.13-0.6x	0.75+0.7x	0.09	N/A
Asset Turnover	N/A	N/A	N/A	0.260.0x	0.25+0.1x	0.15	1.49	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	-269.1%	-262.9%	N/A	-261.2%	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Equity	-27.8%+7958.5pp	N/A	-5.3%	N/A	-7986.3%	N/A	N/A	N/A
Return on Assets	-25.4%+67.5pp	N/A	-4.7%+72.9pp	-42.5%+252.5pp	-92.9%+109.7pp	N/A	-77.6%+7.2pp	-295.0%-268.7pp
Current Ratio	11.57+10.6x	9.30+7.0x	8.83+8.3x	0.71+0.6x	1.01+0.8x	2.33+2.1x	0.52-0.1x	0.11-0.5x
Debt-to-Equity	0.09-84.8x	0.12-0.6x	0.13	N/A	84.94	0.75	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Qualigen Therapeutics, Inc. QLGN	FY2025	N/A	-$17.0M	N/A	$5.4M	—
Galecto, Inc. GLTO	FY2025	N/A	-$209.8M	N/A	$1.7B	—
Silexion Therapeutics Corp SLXN	FY2025	$155K	-$11.9M	N/A	$1.2M	—
Entero Therapeutics, Inc. ENTO	FY2025	$36K	-$6.4M	N/A	$10.1M	—

Where Qualigen Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Qualigen Therapeutics, Inc. profitable?

No, Qualigen Therapeutics, Inc. (QLGN) reported a net income of -$17.0M in fiscal year 2025.

What is Qualigen Therapeutics, Inc.'s return on equity (ROE)?

Qualigen Therapeutics, Inc. (QLGN) has a return on equity of -60.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Qualigen Therapeutics, Inc.'s operating cash flow?

Qualigen Therapeutics, Inc. (QLGN) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Qualigen Therapeutics, Inc.'s total assets?

Qualigen Therapeutics, Inc. (QLGN) had $31.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Qualigen Therapeutics, Inc. spend on research and development?

Qualigen Therapeutics, Inc. (QLGN) invested $185K in research and development during fiscal year 2025.

How many shares does Qualigen Therapeutics, Inc. have outstanding?

Qualigen Therapeutics, Inc. (QLGN) had 5M shares outstanding as of fiscal year 2025.

What is Qualigen Therapeutics, Inc.'s current ratio?

Qualigen Therapeutics, Inc. (QLGN) had a current ratio of 9.30 as of fiscal year 2025, which is generally considered healthy.

What is Qualigen Therapeutics, Inc.'s debt-to-equity ratio?

Qualigen Therapeutics, Inc. (QLGN) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Qualigen Therapeutics, Inc.'s return on assets (ROA)?

Qualigen Therapeutics, Inc. (QLGN) had a return on assets of -54.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Qualigen Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Qualigen Therapeutics, Inc. (QLGN) held $19.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 33 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Qualigen Therapeutics, Inc.'s Piotroski F-Score?

Qualigen Therapeutics, Inc. (QLGN) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Qualigen Therapeutics, Inc.'s earnings high quality?

Qualigen Therapeutics, Inc. (QLGN) reported a net loss of $17.0M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Qualigen Therapeutics, Inc. cover its interest payments?

Qualigen Therapeutics, Inc. (QLGN) reported an operating loss of $13.2M against $989K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.